Cell Viability Assays Market size is expected to surpass USD 19.7 Billion by the end of 2036, growing at a CAGR of 11.5% during the forecast period, i.e., 2024 – 2036. In the year 2023, the industry size of cell viability assays was over USD 5 Billion. The market growth is due to growing interest in developing cell therapy technologies for the treatment of COVID-19 and its increasing acceptance. For example, in 2020, Calidi Biotherapeutics Inc. announced that the Food and Drug Administration had granted provisional marketing authorization for its partner Personalized Stem Cells Inc.'s Investigational New Product Application to be used with stem cell therapy on COVID-19 and pneumonia patients. COVID-19 was reported to WHO by 761,769,759 confirmed cases including 6,784,181 deaths across the globe.
In addition, investment in the area of cell-based research and funding has increased. For example, the California Center for Regenerative Medicine said in February 2022 that it would invest around USD 10 million on a cell therapy study to help patients who have throat cancer recover from terrible radiation side effects.
Base Year |
2023 |
Forecast Year |
2024-2036 |
CAGR |
~ 11.5% |
Base Year Market Size (2023) |
~ USD 5 Billion |
Forecast Year Market Size (2036) |
~ USD 19.7 Billion |
Regional Scope |
|
Growth Drivers
Challenges
Application (Drug Discovery & Development, Stem Cell Research)
The stem cell research is anticipated to account for 52% share of the global cell viability assays market during the forecast period. The growth of this category can be attributed to increasing investments in stem cell research, and the Novo Nordisk Foundation's investment is expected to reach as high as USD 340 million over 10 years for the construction of a global Stem Cell Research Facility by 2022. The growth segment is also projected to benefit from an increase in the incidence of cardiovascular disease. The problems with the blood vessels cause cardiac disease most of the time. Stem cells that appear and function as normal blood vessels are used for the production of new blood vessels. In view of their ability to repair or regenerate various human tissues, stem cells from the bank can be used as a tool for people who are affected by conditions like vascular and cardiac disease.
Product (Consumables, Instrument)
Cell viability assays market from the consumables segment is expected to hold the largest share by the end of 2036. In view of the application of consumables for diagnostics, stem cell research, and pharmaceutical and biopharmaceutical research in particular, this segment is expected to experience significant growth with approximately 55 % market share over the forecast period. A large selection of nontoxic, ready-to-use, and highly immediate results reagents for cell viability assays is also available from a number of market participants.
Our in-depth analysis of the global market includes the following segments:
Product |
|
Application |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this Report
North American Market Forecast
North America region is projected to account for 38% share of the cell viability assays market, supported by an increase in cancer cases and infrastructure for clinical and laboratory research with a quality that has not yet been achieved in North America. a projected 1,806,590 new instances of cancer were identified in the US in 2020, while 606,520 people passed away from the illness. Consequently, it is expected that growth in the product market will be driven by demand for cell-based therapies. The expansion of the research and development capability, coupled with increasing expenditure on developing healthcare infrastructure, has led to a growing need for cell viability assays.
APAC Market Statistics
The cell viability assays market in Asia Pacific is attributed to have about 28% share during the forecast period. The growth of the market may be due to a growing government initiative, which seeks to inform people about an increasing incidence of cancer and different types of cell therapy available. In addition, the government in these areas makes a great deal of investment in research and development. However, cell therapies such as stem cell therapy are also being funded by a variety of private sectors. Consequently, the growth of the market in this region is estimated to be stimulated by these factors. In addition, the growth of this industry is projected to be driven by an increase in demand for biopharmaceutical products as well as a presence of cutting-edge research and healthcare infrastructure throughout the region.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: The majority factors driving the growth of the market are growing geriatric population, rise in prevalence of cancer, surge in need for stem cell transplant, and others.
Ans: The market size of cell viability assays is anticipated to attain a CAGR of 11.5% over the forecast period, i.e., 2024 – 2036.
Ans: The major players in the market are Agilent Technologies, Inc., Bio-Rad Laboratories Inc., Merck KGaA, Becton, Dickinson and Company (BD), PerkinElmer Inc., Promega Corporation, Biotium, Inc., Creative Bioarray, Abcam Plc., and others.
Ans: The stem cell research segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
Ans: The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?